ACADIA & NEU charts YTD, page-5

I would say Trofinetide definitely moves the needle for ACADIA but not nearly as much as NUPLAZID and new indications for Pimavanserin.

The accessible market for Parkinson’s, dementia and possibly Schizophrenia (the last 2 in the pipeline) far outweighs Trofinetide. BUT Trofinetide offers them the opportunity to derisk/diversify from their heavy reliance on Pimavanserin. It was questions over that drug by the FDA that recently put ACADIA shareprice into the toilet..

So I am pretty sure ACADIA is keen to see returns on their US150M+ investment in Trofinetide as soon as possible as is ACADIAs shareholders..


My opinion only. Not investment advice.